Core Viewpoint - Jinsiyaya Pharmaceutical (300434) announced that its wholly-owned subsidiary, Zhejiang Deer Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its Diclofenac Sodium Sustained-Release Tablets (0.1g specification), which have passed the consistency evaluation of quality and efficacy for generic drugs [1] Company Summary - Jinsiyaya Pharmaceutical's subsidiary, Zhejiang Deer Pharmaceutical, has successfully obtained a drug supplement application approval notice [1] - The approved product is Diclofenac Sodium Sustained-Release Tablets, indicating a significant milestone in the company's product portfolio [1] - The approval reflects the company's commitment to meeting regulatory standards and enhancing its market position in the pharmaceutical industry [1]

Group 1 - The core event involves a block trade of 1 million shares of Jinshi Yiyao, with a transaction value of 9.9 million yuan, accounting for 3.29% of the total trading volume on that day [1] - The transaction price was 9.9 yuan per share, which represents an 11.61% discount compared to the market closing price of 11.2 yuan [1] - The trade occurred on November 3, 2025, and was executed by Guotai Junan Securities, with both the buyer and seller being the same brokerage firm [2]

Core Viewpoint - Jinshi Yao (300434) has shown a positive market performance with a closing price of 10.98 yuan, reflecting a 4.87% increase as of October 31, 2025, indicating investor confidence and potential growth opportunities in the company [1]. Group 1: Company Operations - Jinshi Yao has established two subsidiaries in Hainan Province: Hainan Asia Pharmaceutical Co., Ltd. and Hainan Kuaike Pharmaceutical Co., Ltd. [2][3] - The company is actively monitoring the policies of the Hainan Free Trade Zone, which includes industry support, tariff reductions, tax incentives, and talent introduction, to leverage potential business opportunities and explore new growth points [2]. Group 2: Market Activity - On October 31, 2025, the net inflow of main funds into Jinshi Yao was 36.17 million yuan, indicating strong interest from major investors [3]. - Retail investors showed a net outflow of 38.54 million yuan, suggesting a divergence in investment sentiment between institutional and retail investors [3].

Group 1 - The company Jinshi Yiyao (SZ 300434) announced that board member Zheng Zhiyong plans to reduce his holdings by up to approximately 930,000 shares, representing 0.23% of the total share capital, within three months after the announcement [1] - Shareholder Jiang Erchen, who holds about 230,000 shares (0.06% of total share capital), also plans to reduce his holdings by the same amount within the same timeframe [1] - As of the announcement, Jinshi Yiyao's market capitalization is 4.3 billion yuan [1] Group 2 - For the first half of 2025, Jinshi Yiyao's revenue composition is as follows: 82.76% from the pharmaceutical manufacturing industry, 14.09% from the machinery manufacturing industry, and 3.16% from real estate leasing and management [1]

证券代码：300434 证券简称：金石亚药 公告编号：2025-042 四川金石亚洲医药股份有限公司 关于董事、股东减持股份的预披露公告 公司董事郑志勇先生、股东姜二晨先生保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息 一致。 特别提示： 公司董事郑志勇先生，持有本公司股份3,705,304股（占本公司总股本比例 0.92%）计划在减持计划公告之日起十五个交易日后的三个月内以集中竞价交易 或大宗交易方式，减持所持有的本公司股份不超过926,326股（占本公司总股本 比例0.23%）。 公司股东姜二晨先生，持有本公司股份227,000股（占本公司总股本比例 0.06%）计划在减持计划公告之日起十五个交易日后的三个月内以集中竞价交易 或大宗交易方式，减持所持有的本公司股份不超过227,000股（占本公司总股本 比例0.06%）。姜二晨先生为公司持股5%以上股东楼金先生的一致行动人。 四川金石亚洲医药股份有限公司（以下简称"公司"）于近日收到公司董事 郑志勇先生、股东姜二晨先生出具的《关于拟减持四川金石亚洲医药股份有限 ...

Core Points - The stock price of Jinshi Asia Pharmaceutical has decreased by 2.04% on October 29, trading at 10.58 CNY per share with a market capitalization of 4.25 billion CNY [1] - The company has experienced a year-to-date stock price increase of 29.32%, but has seen a decline of 9.26% over the last five trading days [1] Financial Performance - For the period from January to September 2025, Jinshi Asia Pharmaceutical reported a revenue of 708 million CNY, a year-on-year decrease of 6.37%, while the net profit attributable to shareholders increased by 66.47% to 96.77 million CNY [2] - The company's main business revenue composition includes 82.76% from pharmaceutical sales, 14.09% from production line and related sales, and 3.16% from property leasing and management [2] Shareholder Information - As of September 30, the number of shareholders for Jinshi Asia Pharmaceutical is 23,200, an increase of 1.72% from the previous period, with an average of 14,757 circulating shares per shareholder, a decrease of 1.69% [2] Dividend Distribution - Since its A-share listing, Jinshi Asia Pharmaceutical has distributed a total of 170 million CNY in dividends, with 71.91 million CNY distributed over the past three years [3]

Group 1 - The stock price of Jinshi Asia Pharmaceutical has decreased by 2.09% to 10.78 CNY per share as of October 28, with a total market capitalization of 4.33 billion CNY [1] - The company has seen a net outflow of 7.54 million CNY in main funds, with significant selling activity amounting to 2.52 million CNY from large orders [1] - Year-to-date, the stock price has increased by 31.77%, but it has experienced a decline of 5.36% over the last five trading days [1] Group 2 - Jinshi Asia Pharmaceutical, established on July 15, 2004, specializes in the research, production, and sales of pharmaceuticals and health foods, with 82.76% of its revenue coming from drug sales [2] - As of September 30, the company reported a revenue of 708 million CNY for the first nine months of 2025, a decrease of 6.37% year-on-year, while net profit increased by 66.47% to 96.77 million CNY [2] - The company has a total of 23,200 shareholders, reflecting a 1.72% increase from the previous period [2] Group 3 - Since its A-share listing, Jinshi Asia Pharmaceutical has distributed a total of 170 million CNY in dividends, with 71.91 million CNY paid out in the last three years [3]

Macro Highlights - The main goals for the "14th Five-Year Plan" period include significant achievements in high-quality development, substantial improvement in technological self-reliance, breakthroughs in comprehensive reforms, enhanced social civilization, improved quality of life, major progress in building a beautiful China, and a more solid national security barrier [1] - By 2035, the aim is to significantly elevate China's economic, technological, defense, and comprehensive national strength, with per capita GDP reaching the level of moderately developed countries, leading to a happier and better life for the people and basic realization of socialist modernization [1] Trade Relations - The Ministry of Commerce announced that a Chinese delegation led by Vice Premier He Lifeng will engage in economic and trade consultations with the U.S. in Malaysia from October 24 to 27, focusing on important issues in Sino-U.S. economic relations [1] EU Sanctions Response - The Ministry of Commerce expressed strong dissatisfaction and firm opposition to the EU's decision to sanction Chinese companies, including large oil refineries and traders, during the 19th round of sanctions against Russia, emphasizing the need to protect the legitimate rights and interests of Chinese enterprises [2] State-Owned Enterprises Planning - The State-owned Assets Supervision and Administration Commission held a meeting to discuss the "14th Five-Year Plan" for central enterprises, emphasizing the need to align with the strategic mission assigned by the Party Central Committee and to enhance core functions and competitiveness [3] - The meeting highlighted the importance of optimizing layout and structural adjustments in line with national needs and industry trends, and improving the quality of planning through thorough research and unified thinking [3] Foreign Exchange Management - The Deputy Director of the State Administration of Foreign Exchange encouraged the implementation of innovative and integrated exploratory policies in Shanghai, focusing on the use of AI and big data to enhance foreign exchange services [4] - The aim is to improve the cross-border financial service capabilities of Shanghai while balancing financial openness and security [4] Company News - Huagong Technology reported a 40.92% year-on-year increase in net profit for the first three quarters and is planning to issue H-shares for listing in Hong Kong [8] - Yangjie Technology terminated its acquisition of 100% equity in Better Electronics [8] - Xinda Securities received approval for the issuance of up to 10 billion yuan in technology innovation corporate bonds [8] - Shuangliang Energy plans to raise no more than 1.292 billion yuan for projects related to zero-carbon intelligent manufacturing [8] - New Lai Materials' subsidiary plans to invest 2 billion yuan in semiconductor core component projects [8] - Chuanfa Longmang's subsidiary intends to invest 366 million yuan in a 100,000 tons/year lithium dihydrogen phosphate project [8] - Steel Research High-tech plans to establish a subsidiary and new industrial base in Saudi Arabia [8] - Aote Electronics intends to terminate the smart integration project for intelligent outlets [8] - Shengyi Electronics expects a year-on-year net profit increase of 476% to 519% for the first three quarters [8] - Other companies reported significant year-on-year net profit growth, including Tianeng Heavy Industry (1359.03%), Te Yi Pharmaceutical (985.18%), and Zhuanlei Technology (598.09%) [8][9]

Core Insights - The company Jinshi Yao reported a revenue of 216,791,709.92 yuan for the third quarter of 2025, indicating a significant growth in financial performance [2] - The net profit attributable to shareholders reached 31,020,527.86 yuan, reflecting a year-on-year increase of 63.90% [2] Financial Performance - Revenue for Q3 2025: 216.79 million yuan [2] - Net profit for Q3 2025: 31.02 million yuan [2] - Year-on-year net profit growth: 63.90% [2]

Core Insights - The company reported a revenue of 707 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 6.37% [1] - The net profit attributable to shareholders increased to 96.77 million yuan, showing a significant year-on-year growth of 66.47% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 79.01 million yuan, reflecting a year-on-year increase of 51.82% [1] - The basic earnings per share stood at 0.24 yuan [1]